Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 15, 2025
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
GlobeNewswire
·
May 15, 2025
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the …
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 15, 2025
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic …
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
GlobeNewswire
·
May 15, 2025
Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ( …
Avicanna Reports Q1 2025 Results and First Profitable Quarter
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 …
Microbix Reports Results for Q2 Fiscal 2025
GlobeNewswire
·
May 15, 2025
MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2025 ended March 31, …
US Rare Cancer Market FDA Approved Rare Cancer Drug Clinical Trials Insight
GlobeNewswire
·
May 15, 2025
Delhi, May 15, 2025 (GLOBE NEWSWIRE) -- US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 …
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 15, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter …
Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia
GlobeNewswire
·
May 15, 2025
ANN ARBOR, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today that it has officially received its business license to begin …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to …
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging …
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire
·
May 15, 2025
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating …
EDAP Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled …
Axovia Therapeutics Unveils New Preclinical Data for AXV-201, for Treatment of Genetic Obesity Caused by MC4R Mutations, at ASGCT
GlobeNewswire
·
May 15, 2025
LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced that today it will unveil new preclinical proof-of-concept data for novelly …
SBC Medical Group Holdings Announces Approval of Share Repurchase Program and Commencement of Share Repurchases
GlobeNewswire
·
May 15, 2025
IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings (Nasdaq: SBC, “the Company”) today announces that its Board of Directors has approved the following share repurchase program and will commence repurchasing its own shares as early …
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
GlobeNewswire
·
May 15, 2025
Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastases Results presented at 2025 ESMO Breast Cancer Annual Congress BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Carrick …
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
GlobeNewswire
·
May 15, 2025
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. …
QHSLab, Inc. Reports 32% Year-Over-Year Revenue Growth and Expanded Gross Margins in First Quarter 2025
GlobeNewswire
·
May 15, 2025
Revenue increased 32% year-over-year to $645,419, driven by growth in ISP and Allergy Diagnostics Gross margin expanded to 66.6%, reflecting improved product mix and operational efficiencies WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. …